Skip to content
Recall Observatory FDA recall evidence

Exact FDA event identifier

Event 90064

3 recalled-product records grouped only because every row carries this exact official event ID.

Open FDA event record

Event summary

Timeline bucket
April 22, 2022
Product types
Drug
Classifications
Class II
Statuses
Terminated
Recalling firm wording
Pfizer Inc.

Dossier provenance

Source snapshots represented here

  • openFDA Drug Enforcement Report-date coverage June 20, 2012–July 08, 2026 Known gap: openFDA describes 2004-present coverage, but the current export has no report-date records in this interval.

Enforcement coverage uses report dates; product initiation dates can precede those bounds. Device-enrichment coverage uses FDA event_date_initiated.

How coverage and grouping work

Complete imported group

Every recalled product in this event

3 official enforcement rows

Product dates, classifications, firms, and source wording remain attached to their individual rows. Opening this dossier never hides products that did not match a prior timeline filter.

drug · product 1 of 3

Accupril (Quinapril HCl Tablets) 10 mg, 90 Tablets Rx only NDC 0071-0530-23 Distributed by: Parke-Davis Division of Pfizer Inc. NY, NY 10017

D-0872-2022
Recall number
D-0872-2022
Initiated
April 22, 2022
Classification
Class II
Status
Terminated
Recalling firm
Pfizer Inc.
Quantity
2079 bottles

App-derived interpretation

Manufacturing or process control reason.manufacturing_process_control · v1.0.0
CGMP Deviations

These labels are deterministic app interpretations, not FDA categories.

Inspect official wording and provenance

Reason for recall

CGMP Deviations: Contains N-nitrosoquinapril above the acceptable limits.

Code information

Lot: DR9639 Exp. MAR 31 2023

Distribution pattern

Nationwide and Puerto Rico

drug · product 2 of 3

Accupril (Quinapril HCl Tablets) 20 mg, 90 Tablets, Rx only NDC 0071-0532-23 Distributed by: Parke-Davis Division of Pfizer Inc. NY, NY 10017

D-0873-2022
Recall number
D-0873-2022
Initiated
April 22, 2022
Classification
Class II
Status
Terminated
Recalling firm
Pfizer Inc.
Quantity
10,304 bottles

App-derived interpretation

Manufacturing or process control reason.manufacturing_process_control · v1.0.0
CGMP Deviations

These labels are deterministic app interpretations, not FDA categories.

Inspect official wording and provenance

Reason for recall

CGMP Deviations: Contains N-nitrosoquinapril above the acceptable limits.

Code information

Lots: DX8682 Exp. MAR 31 2023; DG1188 Exp. MAR 31 2022

Distribution pattern

Nationwide and Puerto Rico

drug · product 3 of 3

Accupril (Quinapril HCl Tablets) 40 mg, 90 Tablets, Rx only NDC 0071-0535-23 Distributed by: Parke-Davis Division of Pfizer Inc. NY, NY 10017

D-0874-2022
Recall number
D-0874-2022
Initiated
April 22, 2022
Classification
Class II
Status
Terminated
Recalling firm
Pfizer Inc.
Quantity
8346 bottles

App-derived interpretation

Manufacturing or process control reason.manufacturing_process_control · v1.0.0
CGMP Deviations

These labels are deterministic app interpretations, not FDA categories.

Inspect official wording and provenance

Reason for recall

CGMP Deviations: Contains N-nitrosoquinapril above the acceptable limits.

Code information

Lots: DX6031 Exp. MAR 31 2023; CK6260 Exp. MAY 31 2022

Distribution pattern

Nationwide and Puerto Rico